Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29269445 | 1.00 | RET (0.41) | RETEPHA2GPR119P2RX3P2RX2 | |
| SCHEMBL31270202 | 0.85 | GPR119 (0.50) | GPR119 | |
| SCHEMBL31270194 | 0.84 | GPR119 (0.44) | GPR119 | |
| SCHEMBL31694961 | 0.84 | GPR119 (0.41) | EPHA2GPR119ERBB2EPHB4 | |
| SCHEMBL29269377 | 0.84 | GPR119 (0.41) | EPHA2GPR119ERBB2EPHB4 | |
| SCHEMBL29269437 | 0.83 | GPR119 (0.47) | GPR119 | |
| SCHEMBL30283471 | 0.83 | GPR119 (0.47) | GPR119 | |
| SCHEMBL31269965 | 0.80 | GPR119 (0.46) | GPR119 | |
| SCHEMBL31270368 | 0.80 | GPR119 (0.41) | GPR119 | |
| SCHEMBL31270113 | 0.79 | SLC5A1 (0.43) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | disclosed |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | PSMB5, PSMA5, PSMB1 | RET 4687/4885EPHA2 4865/4885GPR119 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.